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Pharmacokinetic Modeling of Ceftiofur Sodium Using Nonlinear Mixed-
Effects in Healthy Beagle Dogs
Abstract
Ceftiofur (CEF) sodium is a third-generation broad-spectrum cephalosporin commonly used in an extra-label
manner in dogs for the treatment of respiratory and urinary system infections. To contribute to the literature
supporting CEF use in companion animals, we have developed a compartmental, nonlinear mixed-effects
(NLME) model of CEF pharmacokinetics in dogs (PK). We then used the mathematical model to predict
(via Monte Carlo simulation) the duration of time for which plasma concentrations of CEF and its
pharmacologically active metabolites remained above minimum inhibitory concentrations (respiratory tract
Escherichia coli spp). Twelve healthy beagle dogs were administered either 2.2 mg/kg ceftiofur-sodium (CEF-
Na) intravenously (I.V) or 2.2 mg/kg CEF-Na subcutaneously (S.C). Plasma samples were collected over a
period of 72 hours post-administration. To produce a measurement of total CEF, both CEF and CEF
metabolites were derivatized into desfuroylceftiofur acetamide (DCA) before analysis by UPLC-MS/MS. No
adverse effects were reported after I.V or S.C dosing. The NLME PK models were parameterized using the
stochastic approximation expectation maximization algorithm as implemented in Monolix 2018R2. A two-
compartment mammillary model with first-order elimination and first-order S.C absorption best described
the available kinetic data. Final parameter estimates indicate that CEF has a low systemic clearance (0.25 L/h/
kg) associated with a low global extraction ratio E = 0.02) and a moderate volume of distribution (2.97 L/kg)
in dogs. The absolute bioavailability after S.C administration was high (93.7%). Gender was determined to be
a significant covariate in explaining the variability of S.C absorption. Our simulations predicted that a dose of
2.2 mg/kg CEF-Na S.C would produce median plasma concentrations of CEF of at least 0.5 µg/mL (MIC50)
for approximately 30 hours.
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Abstract: Ceftiofur (CEF) sodium is a third-generation broad-spectrum cephalosporin commonly 19 
used in an extra-label manner in dogs for the treatment of respiratory and urinary system infections. 20 
To contribute to the literature supporting CEF use in companion animals, we have developed a 21 
compartmental, nonlinear mixed-effects (NLME) model of CEF pharmacokinetics in dogs (PK). We 22 
then used the mathematical model to predict (via Monte Carlo simulation) the duration of time for 23 
which plasma concentrations of CEF and its pharmacologically active metabolites remained above 24 
minimum inhibitory concentrations (respiratory tract Escherichia coli spp). Twelve healthy beagle 25 
dogs were administered either 2.2 mg/kg ceftiofur-sodium (CEF-Na) intravenously (I.V) or 2.2 26 
mg/kg CEF-Na subcutaneously (S.C). Plasma samples were collected over a period of 72 hours post-27 
administration. To produce a measurement of total CEF, both CEF and CEF metabolites were 28 
derivatized into desfuroylceftiofur acetamide (DCA) before analysis by UPLC-MS/MS. No adverse 29 
effects were reported after I.V or S.C dosing. The NLME PK models were parameterized using the 30 
stochastic approximation expectation maximization algorithm as implemented in Monolix 2018R2. 31 
A two-compartment mamillary model with first-order elimination and first-order S.C absorption 32 
best described the available kinetic data. Final parameter estimates indicate that CEF has a low 33 
systemic clearance (0.25 L/h/kg) associated with a low global extraction ratio E = 0.02) and a 34 
moderate volume of distribution (2.97 L/kg) in dogs. The absolute bioavailability after S.C 35 
administration was high (93.7%). Gender was determined to be a significant covariate in explaining 36 
the variability of S.C absorption. Our simulations predicted that a dose of 2.2 mg/kg CEF-Na S.C 37 
would produce median plasma concentrations of CEF of at least 0.5 µg/mL (MIC50) for 38 
approximately 30 hours. 39 
Keywords: Ceftiofur sodium; Pharmacokinetics; NLME; Beagle dogs 40 
 41 
1. Introduction 42 
Ceftiofur sodium (CEF-Na) is a third-generation broad-spectrum cephalosporin (β-lactam antibiotic) 43 
which is effective against Gram-positive, Gram-negative, anaerobic, and β-lactamase producing 44 
bacteria [1]. CEF has been developed and approved for treating bacterial lung diseases in cattle [2], 45 
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swine [3] and in horses [4]. The pharmacokinetics (PK) of CEF has previously been described in cattle 46 
[5-8], camels [9], goats [10], horses [11], sheep [12], swine [1], alpacas [13], and rabbits [14].  47 
The PK of subcutaneous (S.C) CEF crystalline-free acid S.C [15] as well as the PK of CEF-Na S.C [16] 48 
have been previously reported in dogs. However, no detailed description of CEF-Na disposition 49 
kinetics after intravenous (I.V) dosing is currently available in dogs, which prevents a rigorous 50 
assessment of absolute bioavailability in this species. And, despite common off-label use of CEF-Na 51 
in veterinary clinics for canine respiratory disease, no formulation is currently approved for use in 52 
dogs. In-depth knowledge of the time-course of systemic CEF-Na concentrations will aid in the 53 
development of effective CEF-Na formulations for the treatment of canine respiratory and urinary 54 
system infections. 55 
The primary aim of this study was to develop a PK model of CEF disposition kinetics in healthy dogs 56 
after CEF-Na I.V and CEF-Na S.C dosing. To produce data for model building, we administered 57 
either 2.2 mg/kg CEF-Na I.V or 2.2 mg/kg CEF-Na S.C to 12 healthy beagle dogs on two separate 58 
occasions. Nonlinear mixed-effects (NLME) modeling was used for data analysis, to allow for 59 
simultaneous modeling of the I.V and S.C route. Another advantage of NLME modeling lies in the 60 
concurrent estimation of between-subject variability, within-subject (i.e. inter-occasion) variability, 61 
and individual covariate effects on drug pharmacokinetics [17-19]. After model building and 62 
validation, the resulting fit was then used to predict (via Monte Carlo simulations) the duration of 63 
time for which plasma concentrations of CEF and its pharmacologically active metabolites remained 64 
above minimum inhibitory concentrations (MIC50, MIC90) for Respiratory tract Escherichia coli spp – 65 
the most common respiratory and urinary tract pathogens in dogs. 66 
2. Materials and Methods  67 
2.1 Drug Supply and Animals 68 
CEF-Na (Sterile Powder, 1 g; Lot No 1708004.2), was supplied by Qilu Animal Health Products Co., 69 
Ltd (Shandong, China). Six male and 6 female healthy beagle dogs were included in the study design. 70 
Animals ages ranged between 1.5 and 2.5 years old, while dogs weighed between 9 and 12 kg. Dogs 71 
were acclimated to the experimental facilities for a minimum of two weeks before the start of the 72 
study. They were fed with a commercial standard feed (Medium-25, Royal Canin, Shanghai, China) 73 
and had free access to fresh water. Suitability for inclusion by the study veterinarian was evaluated 74 
by physical examination combined with measurement of hematology, clinical chemistry, and 75 
coagulation time parameters. General health observations were performed at least daily. The study 76 
protocols and experimental design were reviewed and approved by the Animal Use and Care 77 
Administrative Advisory Committee of the China Agricultural University (Beijing, PR China, Ethical 78 
Protocol Code #11105-17-E-006). 79 
2.2 Drug Administration and Sample Collection 80 
Dogs were randomly assigned to one of two dosing groups and received either 2.2 mg/kg CEF-Na 81 
I.V or 2.2 mg/kg CEF-Na S.C – using a block design on sex to ensure that 3 males and 3 females were 82 
assigned to each study group. Approximately 2 mL of blood were collected from the cephalic vein of 83 
each dog directly into heparinized tubes at 0, 0.08 (I.V group only), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 84 
12, 24, 36, 48 and 72 hr post drug administration. The samples were then centrifuged at 2,280 g for 10 85 
min. Plasma samples were then stored at −20°C before further analysis.2.3 Analytical Methods 86 
Ceftiofur and desfuroylceftiofur metabolites in plasma samples and standards were derivatized to 87 
desfuroylceftiofur acetamide (DCA) before analysis by UPLC-MS/MS. This protocol is a modification 88 
of existing standard operating procedures for CEF quantification adapted to canine samples [6]. In 89 
this assay, dithioerythritol is used to convert ceftiofur and all desfuroylceftiofur metabolites 90 
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containing an intact β-lactam ring to desfuroylceftiofur. Desfuroylceftiofur was then stabilized by 91 
derivatization with iodoacetamide to DCA and total CEF equivalent concentration (measured as 92 
DCA) was then quantified by UPLC-MS/MS[16]. The lower limit of quantification (LLOQ) for the 93 
analysis was set at 100 ng/mL. The calibration curves were in good linearity (R2 > 0.998) and ranged 94 
from 100 to 5,000 ng/mL. The inter-day and intra-day coefficients of variation – using 200, 1000, and 95 
4000 ng/mL standards – were all below 7.58%, while the mean recoveries ranged from 82.15 to 96 
119.44%. All analyses complied with established guidelines on bioanalytical method validation [20].  97 
2.4 NLME Model Building and Evaluation 98 
No outliers were identified after initial data exploration in Monolix datxplore (2018R2, Lixoft, 99 
France), such that all data could be pooled together for model building. CEF plasma concentration 100 
time‐courses from I.V and S.C dosing were analyzed simultaneously using the stochastic 101 
approximation expectation maximization algorithm as implemented in Monolix 2018R2 (Lixoft, 102 
France). Individual model parameters were obtained by using the full posterior of the conditional 103 
distribution. NLME models were written as described by Sheiner and Ludden [21, 22]: 104 
Equation 1: 105 
 106 
 107 
, , 108 
Where  is the observed concentration of CEF equivalent collected from individual  (of  total 109 
individuals) at time , and  indexes the individual sample times from 1 to .  is the 110 
predicted concentration of CEF at time  dependent on , the vector of individual parameters 111 
(e.g. volume of distribution, clearance).  is the residual error function of  112 
where  is an independent random variable distributed in a standard normal distribution i.e. 113 
. Each individual parameter  was modeled as a combination of the population 114 
mean  (i.e. ) and log-normally distributed error  i.e. . 115 
Convergence of the SAEM algorithm was evaluated by inspection of the stability of the fixed- and 116 
random-effect parameters search as well as the precision of parameter estimates – defined via their 117 
relative standard error (RSE). Standard goodness-of-fit diagnostic plots, including individual 118 
predictions vs. observations, individual weighted residuals (IWRES), and predictions distribution 119 
were used to assess the performances of the candidate models. Normality of the random effects was 120 
assessed using the Shapiro-Wilk test as well as inspection of the full posterior distribution of random 121 
effects and residuals. Selection criteria between competing structural models included the Bayesian 122 
information criteria (BIC) and the precision of the model parameter estimates. The BIC was selected 123 
over the Akaike Information Criterion (AIC) as it tends to favor more parsimonious models [23].  124 
125 
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2.5 Handling of Below Limit Of Quantification (BLQ) Data 126 
Data below the LLOQ were modeled by adding to the likelihood function a term describing the 127 
probability that the true observation lies between zero and the LLOQ. For the calculation of the 128 
likelihood, this is equivalent to the M3 method implemented in NONMEM. 129 
2.6 Random Effects Correlation Estimates 130 
Visual inspection of the scatterplot of random effects as well as Pearson correlation tests were used 131 
to evaluate correlations between model parameters. P < 0.05 were considered as statistically 132 
significant. In agreement with previous literature [22, 24], several samples of the posterior 133 
distribution obtained during the last iteration of the SAEM algorithm, rather than the empirical Bayes 134 
estimate (EBE), were used when producing the scatterplot to better assess correlation between model 135 
parameters. 136 
2.7 Inclusion of Covariate Relationships 137 
The effect of two continuous covariates (BW and age) and one categorical covariate (sex) were 138 
evaluated using the automated Pearson’s correlation test and the ANOVA method as implemented 139 
in Monolix 2018R2. P < 0.05 was used as threshold for statistical significance i.e. for inclusion of a 140 
covariate effect in the final NLME model. Age and BW were normalized by their median value and 141 
log-transformed during the covariate search. 142 
2.8 Monte Carlo Simulations 143 
The minimum plasma concentration of antimicrobial required to inhibit XX% of growth in vitro is 144 
known as the Minimum Inhibitory Concentration XX or MICXX. After model selection and fit, the 145 
model was used to predict for how long CEF plasma concentrations remained above the MIC50 (0.5 146 
µg/mL) and MIC90 (8 µg/mL) for Respiratory tract Escherichia coli spp after administration. This time 147 
period for which concentration remained above MICXX was given the variable name τXX. MIC values 148 
were obtained from previously published canine studies [15]. The R 3.4.4 package Simulx 3.3.0 149 
(Monolix 2018R2) was used to simulate CEF plasma disposition kinetic profiles from final Monolix 150 
run files. 151 
In the first set of simulations, we simulated a population of 500 females and 500 females and virtually 152 
administered CEF-Na at 2.2 mg/kg S.C. Then, we used the PK data from this simulation to produce 153 
prediction distributions of CEF between 0 and 40 hours. 154 
In the second set of simulations, we simulated the median CEF PK of male and female dogs after S.C 155 
dosing with 1 to 5 mg/kg (in steps of .1 mg/kg) of CEF-Na. Using this second simulation set, we were 156 
able to calculate the median τ50 and median τ90 for both males and females as a function of CEF-Na 157 
dosage. 158 
3. Results 159 
3.1 Animals 160 
No noticeable signs of discomfort were observed upon injection of CEF-Na and no complications 161 
resulted from CEF exposure.  162 
3.2 Pharmacokinetic Model 163 
A total of 198 plasma concentrations of CEF and metabolites (measured as DCA by UPLC-MS/MS) 164 
from both I.V and S.C dosing groups were pooled together and simultaneously modeled using 165 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 July 2019                   doi:10.20944/preprints201907.0322.v1
 5 of 12 
 
NLME. Only 4.0 % (8/198) data were found to be below the LLOQ of the UPLC-MS/MS validated 166 
method. A two-compartment mammillary PK model with first‐order elimination and first-order 167 
absorption for the S.C route, was found to best fit the pharmacokinetics of CEF equivalents in plasma 168 
based on standard goodness-of-fit diagnostic plots, precision of parameter estimates (RSE), as well 169 
as comparison of BIC between competing structural models (Figure 1-3) [25]. A log-normal error 170 
model best captured the residual variability in the model (Supplemental Figure A). Individual effects 171 
were approximately log-normally distributed around their respective population mode 172 
(Supplemental Figure B). After inspection of the correlation matrix of the random effects (Figure 4), 173 
a correlation between CEF systemic clearance ( ) and central volume of distribution ( ) was 174 
identified and subsequently included in the structure of the statistical model ( , 175 
P ≤ 0.01). Results from the automated covariate search as implemented in Monolix 2018R2 identified 176 
sex as a significant covariate on CEF subcutaneous absorption rate (P ≤ 0.01). Gender was therefore 177 
included in the final model structure, using the following relationship:  178 
Equation 2: 179 
 180 
Where  is equal to 1 if individual 𝑖 is a female and 0 otherwise.  is the population 181 
subcutaneous absorption rate for male dogs and 𝛽 is the effect of the categorical covariate (i.e. sex) 182 
on . Using final parameter estimates from the model, CEF absorption rate was estimated to be two 183 
times greater in male vs. female dogs. 184 
 185 
Figure 1. Schematic representation of the final model structure used to represent the dynamics of CEF 186 
following I.V and S.C dosing in healthy beagle dogs. A two-compartment pharmacokinetic model with first-187 
order elimination and first-order absorption after S.C dosing with CEF best fitted the observed data. ka: 1-st 188 
order absorption rate following S.C dosing with CEF; CL: CEF systemic clearance; Q: inter-compartmental 189 
clearance; V1: central volume of distribution; V2: peripheral volume of distribution. 190 
 191 
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Figure 2. Standard goodness-of-fit (sGOF) diagnostics: individual predictions vs. observations (log scale). Left 192 
panel: I.V (#RTE: 1); Right panel: S.C (#RTE: 2). The robustness of fit and predictive performances of the final 193 
model were supported by the inspection of the sGOF plots. Blue dots: observations; green line, identity line; 194 
dotted black lines: 90% prediction interval; red dots: censored (i.e. below the quantification limit) data. As 195 
described by Nguyen TH et al (25), observations were displayed on a log-scale to better evaluate the quality of 196 
fit. 197 
 198 
Figure 3. Individual predictions of CEF equivalent plasma concentrations in healthy beagle dogs from the final 199 
selected model. Upper panel: I.V (#RTE: 1, n=6); Lower panel: S.C (#RTE: 2, n=6). Scatter plot of observed (blue 200 
dot) and predicted (dashed purple line) individual concentration vs. time after dosing. The full model was able 201 
to describe the individual time-course of CEF equivalents for all administration schedules with excellent 202 
accuracy, as shown by the quality of the individual fits. Below LLOQ data are represented with red dots. 203 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 July 2019                   doi:10.20944/preprints201907.0322.v1
 7 of 12 
 
 204 
Figure 4. Correlation matrix of the random effects (i.e., the ηi). Most correlations were deemed insignificant 205 
(coefficient ≤ 0.3, P > 0.05), with the exception of the correlation between CEF clearance and volume of 206 
distribution (V1): corr_V1_Cl = 0.99 ± 0.05 (P < 0.05). 207 
 208 
3.3 Parameters Estimates 209 
Final parameter estimates and relevant RSEs are tabulated in Table 1. The precision of the final 210 
estimates was high (RSE ≤ 15%), reflecting an accurate and stable parameterization of the model. The 211 
total systemic clearance of CEF was estimated to be low 0.25 L/kg/h [26], with an estimated volume 212 
of distribution of 4.22 L/kg (2.97 and 1.25 L/kg for the volume of the central and the peripheral 213 
compartment, respectively). 214 
Cardiac output, , was approximated using the formula,  [26]. The global 215 
extraction ratio of CEF ( ) was estimated to be low (  0.02). The absolute bioavailability 216 
of CEF was estimated as 93.7%. 217 
Table 1. Estimated model parameters and their associated inter-individual and inter-occasion 218 
variability for CEF pharmacokinetics in dogs. 219 
Parameter  Symbol  Unit  Point 
estimate  
Relative 
standard (error 
%) 
IIV(%) 
Clearance CL L/h/kg 0.25 2.0 24.6 
Absorption (S.C) Ka 1/h 1.47 11.9 -- 
Central compartment volume of 
distribution  
V1 L/kg 1.72 7.3 18.5 
Peripheral compartment volume 
of distribution 
V2 L/kg 1.25 13.2 37.5 
Inter-compartmental clearance Q L/h/kg 0.16 13.9 -- 
Bioavailability (S.C) F % 93.7 11.2 14.4 
Correlation (CL and V1) corr(cl_v1) % 99.9 5.18 -- 
Coefficient (Ka and sex) 
 
- -0.643 20.1 -- 
IIV: Inter-Individual Variability, expressed as CV%; S.C: Subcutaneous; RSE: Relative Standard Error; --: Model 220 
parameter estimated to converge to a null value and fixed to 0. More details on the abbreviated parameters can 221 
be found in the legend of Figure 1.  222 
223 
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3.4 Model Predictions 224 
The prediction distribution of CEF equivalents over time after 2.2 mg/kg CEF-Na S.C administration 225 
suggests that CEF total concentrations (measured as DCA) would remain below the MIC90 226 
concentration threshold (8 µg/mL) for most of the dosing interval, except for individuals in the upper 227 
percentiles of the simulated population (Figure 5A). Also, because male dogs had a higher estimated 228 
CEF absorption rate than females, their peak exposure (i.e. Cmax) was predicted to be greater than in 229 
female dogs.  230 
Results from our model-based simulations suggest that after one dose of 2.5 mg/kg CEF-Na S.C, 231 
ceftiofur concentrations would remain above the MIC50 threshold (0.5 µg/mL) for almost 1.5 days in 232 
both male and female dogs (Figure 5B). 233 
In contrast, our predictions of median τ90 as a function of dosage indicate that even when 234 
administered at unrealistically large doses of CEF-Na S.C (~ 5 mg/kg), CEF concentrations would 235 
remain above MIC90 levels for no more than 8 hours (Figure 5C).  236 
 237 
Figure 5A 238 
 
Figure 5B 
 
Figure 5C 
Figure 5. A. Prediction distribution of CEF pharmacokinetics. Left panel: I.V (#RTE: 1); right panel: S.C (#RTE: 239 
2). The theoretical distribution of CEF PK was produced by 500 Monte Carlo simulations from the final model. 240 
Briefly, the experiment was replicated virtually 500 times, allowing for each quantile (from 5 to 95 in steps of 5 241 
i.e. {5,10,15,…,90,95}) to be estimated 500 times. The blue areas are ranges of quantiles and the blue points are 242 
observations for comparison. In a second step, simulations were used to predict for how long CEF plasma 243 
concentrations remained above the MIC50 (0.5 µg/mL) and MIC90 (8 µg/mL) for Respiratory tract Escherichia 244 
coli spp in both males and females dogs after administration CEF-Na at 2.2 mg/kg S.C. Specifically, the median 245 
PK of males and females after S.C dosing with 1 to 5 mg/kg of CEF-Na was simulated to derive the median τ50 246 
(Figure 5B; left panel: male; right panel: female) and median τ90 (Figure 5C; left panel: male; right panel: 247 
female) as a function of CEF-Na dosage. 248 
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4. Discussion 249 
Since 1991, Ceftiofur has been approved and extensively used by veterinarians in the treatment of 250 
bacterial infections in cattle, swine, and horses. This study constitutes the very first pharmacokinetic 251 
report of CEF-Na absolute bioavailability in dogs, allowing for the proper estimation of CEF systemic 252 
clearance and volume of distribution (as opposed to apparent clearance and distribution volume 253 
estimated with extravascular dosing of CEF-Na). Previously, the PK of ceftiofur in dogs has only been 254 
described in two studies. First, the PK of a single subcutaneous dose of ceftiofur crystalline-free acid 255 
has been described using noncompartmental analysis [15]. Second, the PK of CEF-Na S.C has been 256 
reported using non-linear least squares regression [16]. Results from our analysis suggest that the 257 
absolute bioavailability of CEF-Na S.C is higher in dogs than in cattle (61.12%) [6], while CEF 258 
apparent systemic clearance (CL/F) is lower in dairy cows vs. dogs (0.12 vs. 0.26 L/h/kg) [6]. 259 
In our analysis, CEF and desfuroylceftiofur metabolites (containing an intact β-lactam ring) in plasma 260 
samples were derivatized to DCA [16], and total CEF equivalent concentrations (measured as DCA) 261 
were quantified by UPLC-MS/MS. Free concentrations only accounts for about 10% of total CEF 262 
equivalents[6]. However, protein binding of desfuroylceftiofur is known to be reversible, such as 263 
protein-bound desfuroylceftiofur acts as a reservoir for release of active therapeutic drug at the site 264 
of infection [27]. Hence, measurement of DCA regardless of protein binding was used for simulation 265 
of what-if scenarios and dose optimization in our experiment. 266 
NLME models are a versatile statistical tool for quantifying variability in drug disposition as a 267 
function of individual patient characteristics (i.e. covariates, such as age, sex and bodyweight) [28-268 
30]. NLME modeling also enables decoupling of intra-individual variability, inter-individual 269 
variability, and residual error. This allows to individually consider the many factors that could affect 270 
drug exposure in any given individual. Pooling data from I.V and S.C dosing with CEF (totaling 198 271 
concentrations), the disposition kinetics of CEF equivalents was best modeled using a two-272 
compartmental mammillary model with first-order elimination and first-order absorption from the 273 
S.C injection site. Our final selected model precisely captured the individual PK of total CEF 274 
equivalents over time in both dosing groups. Results from the automated covariate analysis in 275 
Monolix 2018R2 further suggest that sex has a significant effect ( = -0.643 ± 20.1%) on CEF 276 
absorption rate following subcutaneous administration. This was also supported by the inspection of 277 
the distribution of the estimated individual absorption parameters (i.e. kai). Specifically, CEF 278 
absorption rate was estimated to be two times greater in male vs. female dogs, and our model-based 279 
simulations confirmed the potential need for dose adjustment based on sex in dogs. To the best of 280 
our knowledge, no previous studies had reported an effect of sex on ceftiofur PK in dogs or any other 281 
species.  282 
Importantly, using final parameters estimates from the NLME model, we could simulate ‘what-if’ 283 
scenarios to evaluate various dosing schedules for CEF-Na S.C in dogs. The most important risk 284 
factor for emergence of resistance is repeated exposure of bacteria to suboptimal concentrations of 285 
antimicrobials related to the selection of inappropriate dosing schedules [30]. As a cephalosporin 286 
antibiotic, CEF exhibits time-dependent bactericidal activity i.e. plasma concentrations of CEF must 287 
be maintained over relevant MIC levels for an extended period of time. As such, the amount of time 288 
that CEF concentrations remain above the MICXX (i.e. τxx) is the PK-PD best index for predicting drug 289 
efficacy [31].  290 
According to previous research with cephalosporins, τxx should be at least 50% (and preferably ≥ 80%) 291 
of the dosage interval to achieve optimal bactericidal effect without inducing resistance [32]. 292 
Based on these guidelines, our simulations predict a spectrum of viable dosing regimens for CEF-Na 293 
subcutaneous in dogs for Escherichia coli spp. However, producing a definitive recommendation of 294 
dosing interval for CEF in dogs was not within the primary scope of this study. As such, further 295 
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studies in client-owned animals with clinical disease are required to validate and build on our 296 
preliminary findings in healthy dogs. 297 
5. Limitations 298 
Our study had several limitations. First, this experiment was performed in healthy dogs and model-299 
based predictions of CEF disposition kinetics may not extend to dogs with bacterial infection, 300 
impaired hepatic function, or impaired renal function. Second, we chose to refer to MIC values from 301 
previous studies rather than culturing clinical pathogens as a part of the sampling process. Finally, 302 
and with respect to our experimental design, this study solely reports the disposition kinetics of CEF 303 
after a single dose of CEF-Na, with no information about systemic accumulation and steady-state 304 
pharmacokinetics of CEF in dogs.  305 
Supplementary Materials: The following are available online at 10.5281/zenodo.3348395, Figure A and Figure 306 
B.  307 
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